ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE

Ad-RTS-hIL-12 (Ad) is a novel gene therapy, conditionally expressing IL-12 via the RheoSwitch Therapeutic System® (RTS®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported results from 51 subjects (NCT02026271 and NCT03679754) describing biological activity...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Lukas, Rimas, Chiocca, Ennio, Kurz, Sylvia, Yu, John, Landolfi, Joseph, Rao, Ganesh, Buck, Jill, Demars, Nathan, Smith, Amy, Miao, John, Zhou, John, Wang, Yunxia, Gelb, Arnold, Cooper, Laurence
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Adult Clinical Trials–Immunologic
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.018
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak